Author: equipe

CellProthera recently announced positive results from a Phase 1/2b study of its lead ProtheraCytes in patients following a severe heart attack, positioning the stem cell therapy as a promising option to repair and regenerate heart tissue. The data was presented today by Faiez Zannad, MD, PhD, Chairman of the study’s steering committee and emeritus professor of therapeutics at the Université of Lorraine.

  • Upcoming clinical trials, led by stem cell pioneer Professor Takayuki Asahara, will use CellProthera’s StemXpand® and StemPack® technology to manufacture endothelial progenitor cells (EPCs)
  • This collaboration is the first to bring CellProthera’s manufacturing systems to Japan, following successful use of the systems in clinical trials in Europe